ATE97803T1 - Therapeutische verwendung von 5-ht3-rezeptorantagonisten. - Google Patents

Therapeutische verwendung von 5-ht3-rezeptorantagonisten.

Info

Publication number
ATE97803T1
ATE97803T1 AT90905482T AT90905482T ATE97803T1 AT E97803 T1 ATE97803 T1 AT E97803T1 AT 90905482 T AT90905482 T AT 90905482T AT 90905482 T AT90905482 T AT 90905482T AT E97803 T1 ATE97803 T1 AT E97803T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
therapeutic use
disorders
agoraphobia
useful
Prior art date
Application number
AT90905482T
Other languages
English (en)
Inventor
Alberto Azcona
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898909147A external-priority patent/GB8909147D0/en
Priority claimed from GB898916602A external-priority patent/GB8916602D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE97803T1 publication Critical patent/ATE97803T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT90905482T 1989-04-21 1990-04-06 Therapeutische verwendung von 5-ht3-rezeptorantagonisten. ATE97803T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898909147A GB8909147D0 (en) 1989-04-21 1989-04-21 Improvements in or relating to organic compounds
GB898916602A GB8916602D0 (en) 1989-07-20 1989-07-20 Improvements in or relating to organic compounds
EP90905482A EP0422154B1 (de) 1989-04-21 1990-04-06 Therapeutische verwendung von 5-ht3-rezeptor-antagonisten
PCT/EP1990/000540 WO1990012569A1 (en) 1989-04-21 1990-04-06 Therapeutic use of 5-ht3 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE97803T1 true ATE97803T1 (de) 1993-12-15

Family

ID=26295258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90905482T ATE97803T1 (de) 1989-04-21 1990-04-06 Therapeutische verwendung von 5-ht3-rezeptorantagonisten.

Country Status (10)

Country Link
EP (1) EP0422154B1 (de)
JP (1) JPH0669963B2 (de)
KR (1) KR920700034A (de)
AT (1) ATE97803T1 (de)
AU (1) AU631632B2 (de)
CA (1) CA2031214A1 (de)
DE (1) DE69004924T2 (de)
DK (1) DK0422154T3 (de)
ES (1) ES2061024T3 (de)
WO (1) WO1990012569A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276050A (en) * 1989-08-01 1994-01-04 Glaxo Group Limited Medicaments
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
EP0641198A1 (de) * 1992-05-23 1995-03-08 Smithkline Beecham Plc Arzneimittel zur behandlung von angstzuständen
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
JP5387648B2 (ja) 2011-10-14 2014-01-15 株式会社デンソー 指針表示装置

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1365296A (en) * 1970-10-30 1974-08-29 Unilever Ltd Dentifrice compositions
EP0099194A3 (de) * 1982-07-03 1984-04-11 Beecham Group Plc Benzamide
NO164025C (no) * 1984-01-25 1990-08-22 Glaxo Group Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-imidazolylmetyl-tetrahydrokarbazolon-derivater.
AU583343B2 (en) 1985-01-23 1989-04-27 Glaxo Group Limited Heterocyclic compounds
DE385517T1 (de) * 1985-03-14 1991-07-25 Beecham Group p.l.c., Brentford, Middlesex Arzneimittel zur behandlung von erbrechen.
GB8518745D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518743D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518741D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
EP0212398A2 (de) 1985-08-21 1987-03-04 Siemens Aktiengesellschaft Verfahren zur Erkennung von Mehrfrequenzcodesignalen mit überlagerten Störsignalen
IL80707A (en) 1985-12-23 1991-03-10 Hughes Aircraft Co Gaseous discharge device simmering circuit
CA1303047C (en) 1986-03-17 1992-06-09 Alexander W. Oxford Imidazolyl indole derivatives
GB8701494D0 (en) 1987-01-23 1987-02-25 Glaxo Group Ltd Chemical compounds
GB8617994D0 (en) 1986-07-23 1986-08-28 Glaxo Group Ltd Heterocyclic compounds
EP0254584B1 (de) * 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
GB8623819D0 (en) 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
DE3777805D1 (de) 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
GR871809B (en) 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
PH23937A (en) * 1986-12-16 1990-01-23 Robins Co Inc A H Anxiolytic-n-(1-azabicyclo(2.2.2.)oct-3-yl)benzamides and thiobenzamides
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
US4918080A (en) 1987-04-14 1990-04-17 Glaxo Group Limited Imidazollyl containing ketone derivatives
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
GB8720693D0 (en) 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
NZ226032A (en) 1987-09-03 1991-12-23 Glaxo Group Ltd 2-(imidazolylmethyl)-pyrido or-azepino(4,3-b)indole-1(2h)-one derivatives; preparatory processes and pharmaceutical compositions
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
EP0317088A1 (de) 1987-10-22 1989-05-24 Glaxo Group Limited Ketonderivate
DE3740984A1 (de) * 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
GB8802127D0 (en) 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
EP0329932B1 (de) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln
EP0329904A1 (de) * 1988-02-23 1989-08-30 Merrell Dow Pharmaceuticals Inc. Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln zur Behandlung von Anxietas
EP0336759A1 (de) 1988-04-07 1989-10-11 Glaxo Group Limited Imidazol-Derivate
EP0339959A3 (de) 1988-04-27 1991-03-20 Glaxo Group Limited Laktam-Derivate
US4863921A (en) 1988-04-27 1989-09-05 Rorer Pharmaceutical Corporation Dibenzofurancarboxamides and their pharmaceutical compositions and methods
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU5415890A (en) 1990-11-16
EP0422154B1 (de) 1993-12-01
DE69004924T2 (de) 1994-05-19
KR920700034A (ko) 1992-02-19
JPH03505881A (ja) 1991-12-19
CA2031214A1 (en) 1990-10-22
EP0422154A1 (de) 1991-04-17
DE69004924D1 (de) 1994-01-13
ES2061024T3 (es) 1994-12-01
WO1990012569A1 (en) 1990-11-01
AU631632B2 (en) 1992-12-03
JPH0669963B2 (ja) 1994-09-07
DK0422154T3 (da) 1994-03-07

Similar Documents

Publication Publication Date Title
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE291011T1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE69623970D1 (de) Formulierung von d-threo methylphenidat mit verzögerter freisetzung
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE68917268D1 (de) Die Verwendung von ausgewählten amphiphilen Copolymeren in der Behandlung von Leder.
KR900009079A (ko) 비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
DE69625516D1 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE69429299D1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE97803T1 (de) Therapeutische verwendung von 5-ht3-rezeptorantagonisten.
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
DE69010172D1 (de) Verfahren zur Vermögenserhöhung von elektroakustischen Tieffrequenzwandlern und damit übereinstimmende Wandler.
DE69131398D1 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ATE130868T1 (de) Verwendung von mischungen von mannich-acrylamid- polymeren und dimethyldiallylammoniumhalidpolymeren zur ausflockung von enzymbrühen.
DE69808455D1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
ATE303158T1 (de) Verwendung von beta-interferon zur behandlung der restenose
DE68929177D1 (de) Verwendung von Dihydropyridinen zur Vorbeugung und Behandlung cerebraler Durchblutungsstörungen
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
REN Ceased due to non-payment of the annual fee